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Abstract: Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. 
These receptors play an important role in the regulation of inflammatory reactions and sensing cellular damage. They have 
also been implicated in the pathogenesis of various diseases, including neurodegenerative diseases, cataract formation, 
and atherogenesis. Thus, FPR ligands, both agonists and antagonists, may represent novel therapeutics for modulating 
host defense and innate immunity. A variety of molecules have been identified as receptor subtype-selective and mixed 
FPR agonists with potential therapeutic value during last decade. This review describes our efforts along with recent ad-
vances in the identification, optimization, biological evaluation, and structure–activity relationship (SAR) analysis of 
small molecule non-peptide FPR agonists and antagonists, including chiral molecules. Questions regarding the interaction 
at the molecular level of benzimidazoles, pyrazolones, pyridazin-3(2H)-ones, N-phenylureas and other derivatives with 
FPR1 and FPR2 are discussed. Application of computational models for virtual screening and design of FPR ligands is 
also considered. 
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molecular modeling. 
1. INTRODUCTION
Formyl peptide receptors (FPRs) are G protein-coupled
receptors (GPCR) that play an important role in leukocyte 
activation and chemotaxis [1]. These receptors were origi-
nally identified for their ability to bind and be stimulated by 
N-formyl peptides, which are produced by bacteria but can 
also be released from damaged mitochondria during tissue 
injury [2-4]. Phylogenetic analysis has revealed that FPRs 
belong to a family of chemosensory GPCR [5], and structur-
ally related members of these receptors expressed in the vo-
meronasal organs of mammals appear to have an olfactory 
function associated with the identification of pathogenic 
states [6, 7]. It has been proposed that FPRs act as sensors of 
pathogen-derived products that recruit leukocytes to sites of 
infection, where these cells exert antibacterial effector func-
tions and clear cell debris [8, 9]. Indeed, targeted disruption 
of the fpr1 gene coding for the mouse counterpart of human 
FPR1 renders mice more susceptible to bacterial infection 
without other significant phenotypic alterations [10], sup-
porting the role of FPRs in innate host defense based on rec-
ognition of bacterial-derived agonists. However, the expres-
sion pattern of FPRs in nonphagocytic cells suggests that 
these receptors also participate in functions other than innate 
immunity and may represent unique targets for therapeutic 
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drug design [9, 11-13]. For example, it was recently found 
that aging Fpr1 knockout mice develop spontaneous lens 
degeneration, suggesting FPR agonists may be useful in drug 
therapy for cataracts [14].  
In humans, there are three FPR isoforms: FPR1 and 
FPR2 exhibiting 69% amino acid homology to each other, 
and FPR3 with 56% amino acid sequence identity to FPR1 
and 83% to FPR2 [1]. These receptors are expressed on a 
variety of cell types, including neutrophils, macrophages, T 
lymphocytes, immature dendritic cells, epithelial cells, 
hepatocytes, fibroblasts, astrocytes, microvascular endothe- 
lial cells, and platelets [1, 15-17]. In mice, the FPR family 
consists of eight genes, including genes for mFpr1, mFpr2, 
and mFpr-rs1, which are expressed in leukocytes. Recently, 
mFpr1/mFpr2 was found to be expressed in dendritic and 
glial cells [8, 18-20]. Five distinct Fprs, including mFpr-rs1, 
mFpr-rs3, mFpr-rs4, mFpr-rs6, and mFpr-rs7, are expressed 
in mouse vomeronasal sensory neurons [5]. Mouse Fpr1 has 
a 76% sequence identity to human FPR1; however, its 
putative ligand-binding domains resemble those of human 
FPR2 rather than FPR1 [8, 21].  
Being expressed in the majority of white blood cells, 
FPRs play an important role in the regulation of 
inflammatory reactions and cellular dysfunction [15, 22]. A 
variety of endogenous and pathogen-associated molecules 
can bind FPR1 and FPR2 with high affinity. Several studies 
have described intestinal proinflammatory properties for N-
formyl peptides (e.g., fMLF), such as in colonic 
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inflammation in vivo [23-25], suggesting a possible role in 
the etiology of inflammatory bowel disease in humans when 
bacterial chemotactic peptides breach mucosal defenses. 
Furthermore, involvement of fMLF in the pathogenesis of 
pouchitis, ulcerative colitis, and Crohn’s disease is also 
suggested [26-28]. Fehr et al. [29] reported that fMLF could 
substitute for the place of the second endotoxin injection in 
provoking the generalized Shwartzman reaction in rabbits. 
When injected into rabbits, fMLF causes dose-dependent 
transient hypotension, as well as neutropenia, thrombo- 
cytopenia, and a decrease in systemic vascular resistance 
[30, 31]. Moreover, fMLF causes a variable degree of 
bronchoconstriction after inhalation of this peptide by rabbits 
[32]. Similarly, leucopenia occurs rapidly after inhalation of 
fMLF by humans and could contribute to bronchial inflam-
mation during bacterial infection [33].  
FPR2 behaves as a “pattern recognition” receptor that can 
be activated by a wide variety of unrelated ligands. These 
include acute-phase serum amyloid A (SAA), annexin 1, 
urokinase plasminogen activator receptor (uPAR), the V3 
region of HIV-1 envelope glycoprotein gp120, a 42-amino-
acid form of ?-amyloid, human prion peptide, cathelicidin 
LL-37, and other molecules (reviewed in [1, 11, 34, 35]). 
Some of these endogenous FPR2 agonists may play patho-
physiological roles. For example, binding of SAA to FPR2 
contributed to the destruction of bone and cartilage via the 
promotion of synoviocyte hyperplasia and angiogenesis in 
rheumatoid arthritis [36]. Recently, it was proposed that 
FPR2 could be involved in pathogenic mechanisms of 
atherogenesis via FPR2-dependent SAA-stimulated foam 
cell formation [37, 38]. Other examples of FPR involvement 
in multiple diseases have been recently reviewed [39]. These 
authors concluded that FPRs form a very attractive family of 
pharmacological targets and suggested that “the studies of 
specific agonists and antagonists for FPRs will be of great 
significance for better understanding of the roles of these 
receptors in physiology and pathophysiology [39].”  
2. THERAPEUTIC EFFICACY OF FPR LIGANDS 
Various approaches to activate or inhibit FPR-dependent 
pathways have been considered for therapeutic development. 
For example, antagonists that inhibit binding of FPR ago-
nists decrease leukocyte chemotaxis and can potentially di-
minish release of pro-inflammatory molecules. In addition, 
some of therapeutic effects of FPR agonists may be related 
to homo- and/or cross-desensitization mechanisms. Finally, 
an integral role of FPR agonists in promoting the resolution 
of inflammatory reactions has been demonstrated [40, 41]. 
There is evidence that bioactive ligands acting as FPR 
agonists or antagonists might serve as useful therapeutics in 
host defense and as immunomodulatory activators to en-
hance selective innate immune responses in order to reduce 
detrimental effects associated with inflammation, infectious 
diseases, and cancer [42-45]. Various endogenous and syn-
thetic peptide FPR agonists have been used to study the po-
tential therapeutic efficacy in models of pathological proc-
esses. For example, FPR2 agonist, annexin 1 fragment 2-26 
(Anxa12–26), reduced the lipopolysaccharide (LPS)-induced 
cerebrovascular inflammatory response in a murine model 
[46], significantly enhanced gastric ulcer healing [47], and 
prevented reperfusion-induced myocardial dysfunction in 
rats [48]. In addition, both Anxa12–26 and fMLF induced anti-
nociceptive effects in mice [49]. The FPR2 agonist CGEN-
855A (21-amino acid peptide) displayed anti-inflammatory 
activity in a mouse air pouch model and provided protection 
against ischemia-reperfusion-mediated injury to the myocar-
dium in both murine and rat models [50]. It has also been 
suggested that FPR agonists could be utilized as anti-HIV 
therapeutics/immunoregulators to mobilize phagocytic leu-
kocytes in HIV/AIDS patients [51, 52]. One of most potent 
mixed-type FPR agonists, a D-methionine-containing 
hexapeptide WKYMVm, potently inhibited HIV-1 Env-
mediated fusion and viral infection through heterologous 
desensitization of C-X-C chemokine receptor 4 (CXCR4) 
and C-C chemokine receptor 5 (CCR5), suggesting a novel 
approach to the development of anti-HIV-1 therapeutics 
[53]. WKYMVm also increased neutrophil bactericidal ac-
tivity in chemotherapy-treated cancer patients [54], protected 
the host by enhancing bactericidal activity and inhibiting 
vital organ inflammation and apoptosis in a sepsis mouse 
model [55], and enhanced endogenous tumor necrosis factor 
(TNF)-related apoptosis inducing ligand (TRAIL) gene ex-
pression with tumoricidal activity [56]. Furthermore, airway 
activation of FPRs with WKYMVm effectively prevented 
the development of allergic inflammation induced by inhala-
tion of LPS-containing allergens. This effect was mediated 
by the inhibition of dendritic cell infiltration, maturation, and 
migration, as well as inhibition of both Th1 and Th17 polari-
zation [57]. Based on localization of FPRs in leukocytes and 
in the central nervous system, these receptors have also 
emerged as promising therapeutic targets for the treatment of 
neurodegenerative diseases [58]. In addition, peptide ago-
nists of FPR1 and FPR2 (i.e., fMLF and MMK-1, respec-
tively) prevented alopecia in neonatal rats induced by the 
anticancer agent etoposide [59]. 
The most potent and receptor specific FPR1 antagonists 
described so far are the fungal hydrophobic cyclic peptides, 
cyclosporines A and H [60]. Although cyclosporine H at-
tenuated the acute inflammatory response evoked by ciga-
rette smoke [61] and blocked fMLF-induced analgesia [62], 
in vivo studies of cyclosporines should be interpreted care-
fully because their main therapeutic effects appear to involve 
signaling pathways unrelated to FPR1 [63]. Indeed, cy-
closporin A, a relatively large molecule (1.2 kDa), inhibited 
the T-cell receptor signal transduction pathway via the for-
mation of a cyclosporin A-cyclophilin complex, which in 
turn bound to and inhibited the Ca2+-calmodulin dependent 
phosphatase calcineurin [64]. Cyclosporin A also inhibited 
formation and opening of the mitochondrial permeability 
transition pore [65]. Although cyclosporine H does not bind 
to immunophilin, this peptide is a potent inhibitor of the 
Ca2+-calmodulin-dependent phosphorylation of elongation 
factor 2 (EF-2) [66].  
Other known peptide FPR antagonists are Boc-MLF (also 
termed Boc-1), and Boc-FLFLFL (also termed Boc-2), and 
there are several reports of in vivo application of Boc-2 [46, 
48, 67, 68]. For example, Anxa12–26-induced cardioprotec-
tion was abolished by Boc-2 [48]. Similarly, Boc-2 pre-
vented the inhibitory effect of Anxa12–26 on neutrophil ex-
travasation [68]. Recently, tryptophan containing dipeptide 
derivatives of Boc-2 were reported as FPR1 antagonists [69].  
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The number of novel synthetic peptide FPR ligands con-
tinues to increase, and there are a couple of excellent reviews 
in the past few years summarizing these molecules [11, 43, 
58, 70-73]. However, peptides are difficult to make and ad-
minister as therapeutic agents, making small-molecule 
chemical compounds a better choice for future clinical de-
velopment. Growing evidence supporting the anti-
inflammatory and tissue-protective effects of FPR agonists 
and antagonists prompted us and other research groups to 
search for novel small-molecule ligands for these receptors. 
As result of these efforts, a great number of synthetic non-
peptide FPR agonists and antagonists with a wide range of 
chemical diversity were found using different high-
throughput platforms in screening of commercial libraries 
and/or by structure–activity relationship (SAR)-directed de-
sign and synthesis (e.g., [74-87]). These have great potential 
for development of clinically useful anti-inflammatory and 
immunomodulatory drugs [85]. The availability of structur-
ally defined non-peptide small-molecule FPR ligands is 
clearly of substantial benefit in drug development and facili-
tating SAR analysis to model ligand binding features, which 
is somewhat difficult with peptide ligands.  
In this review, we provide an overview of the current lit-
erature, perspectives regarding therapeutic potential of vari-
ous FPR ligands, details on the discovery and design of 
novel small-molecule non-peptide FPR agonists and antago-
nists. Because there have been ongoing efforts in several 
laboratories to study “FPR–ligand” interaction, questions 
regarding molecular modeling of FPR recognition are also 
discussed. 
3. SMALL-MOLECULE FPR AGONISTS AND THEIR 
MODELING 
Although using the chemical structure of endogenous 
ligands is one strategy for design of synthetic GPCR agonists 
and antagonists, this strategy has not been exploited in the 
development of non-peptide FPR ligands. Indeed, only 
lipoxin A4 (LXA4) and bile acids have been reported to date 
as endogenous non-peptide FPR ligands [88, 89]. Although 
LXA4 has been described as an anti-inflammatory mediator 
that exerts its effects through FPR2, the LXA4 target has 
been a matter of debate, as LXA4 analogues have been re-
ported to be unable to signal through FPR2 [90-93]. In any 
case, most primary strategies for identifying new FPR ago-
nists have been high-throughput screening (HTS), SAR 
analysis, and computer-aid drug design.  
3.1. Benzimidazole Derivatives 
HTS of a chemical library of synthetic small-molecule 
compounds identified two FPR1-specific agonists 1 and 2, 
which have a common 2-(benzimidazol-2-ylsulfanyl)-N-
phenyl-acetamide scaffold [79]. Both compounds activated 
chemotaxis in human neutrophils, and SAR analysis of 52 
related derivatives revealed 17 additional FPR1-specific 
agonists and 16 mixed FPR1/FPR2 agonists [79, 82]. 
Selected FPR agonists 1-9 with the benzimidazole scaffold 
are shown in (Table 1). It should be noted that all active 
derivatives contained either a 5-methoxy or 5-ethoxy group 
in the benzene moiety of the benzimidazole heterocycle, 
which was an essential feature for activity. Modification of 
benzene ring A also had effects on activity and receptor 
specificity, although a wider range of modifications was 
tolerated in this ring, including such substituents in the para 
position as nitro (1), ethoxy (2), methoxy (3 and 4), chlorine 
(5), bromine (6), methylthio (7), and methylcarboxyl (8) 
(Table 1). However, if the alkoxy chain on benzene ring A in 
3 was elongated to four carbons, activity was lost. 
Introduction of an additional chlorine in compound 5 at the 
meta position resulted in complete loss of activity. Likewise, 
substitution of the para methoxy group in compounds 3 and 
4 with trifluoromethoxy led to partial or complete loss of 
FPR1 agonist activity. All tested derivatives where benzene 
ring A contained fused 1,3-dioxolane or 1,4-dioxane rings 
were FPR agonists, although only compound 9 was specific 
for FPR1, and the other compounds with this feature were 
mixed FPR1/FPR2 agonists [82]. 
3.1.1. Molecular Docking of Benzimidazole Derivatives 
In the absence of an experimentally determined structure 
of FPR1, homology modeling can provide a rational alterna-
tive to a reasonable 3D structure. The FPR1 homology 
model was created using the crystal structure of bovine 
rhodopsin, which has a sequence identity of 20% for 348 
aligned residues that correspond to the seven transmembrane 
domains [82, 94]. The position of the ligand binding site in 
the homology model, based on cross-linking and mutagene-
sis studies, was found to be located in the upper region of a 
bundle comprising transmembrane helices 2, 5, 6, and 7 [95, 
96] and was confirmed by docking studies with tetrapeptide 
Ac-QAWF, which is the shortest core structure of the an-
nexin AI-derived peptide [94]. Since pre-docking studies 
indicated that this region is coincident with the ligand bind-
ing site, it was proposed that this feature is relevant to the 
modeling process [97] and justified use of the rhodopsin-
based model as a template for the docking of novel small-
molecule FPR1 agonists vs. the other known GPCR crystal 
structures currently available. 
Key sub-areas of the FPR1 binding site include two 
channels (A and C), two cavities (B and E), and the bottom 
(D) [82] (see arrows in Fig. 1A). Docking studies [82] 
showed that, most active FPR1-specific agonists 7 and 8 
both had very similar benzimidazole orientations with their 
methoxy substituents H-bonded to Thr199 in channel A of 
the FPR1 binding site (Fig. 1B). Compound 8 forms a H-
bond of 1.5 kcal/mol with a key residue (Arg205), and this 
interaction was weaker than the H-bond formed between 
Arg205 and fMLF. Thirty seven of 43 related alkoxy-
substituted benzimidazoles had methoxy or ethoxy oxygen 
atoms embedded in channel A of the FPR1 binding site or in 
cavity B, which is located behind the hydrophobic ledge 
formed by the isobutyl group of Leu198. Thirty-four of these 
benzimidazole compounds were active FPR1 agonists, dem-
onstrating the importance of the ligand–receptor interactions 
in regions A and B for FPR1 agonist activity. As examples, 
positions of alkoxy groups in the binding site are shown in 
Fig. 1A for FPR1 agonists 1, 7, and 8.  
3.2. Pyrazolones 
Using a Ca2+ flux-based assay in G?15 and FPR1/FPR2 
co-transfected CHO cells for HTS of a small-molecule 
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chemical library, researchers from Amgen identified pyra-
zolone 10 as a potent FPR2 agonist [98]. Replacement of the 
iodine atom in position 4 with other halogens resulted in 
decreased potency, which correlated with the size of the 
halo-substituent (compounds 11 and 12) (Table 2). However, 
the analog with an unsubstituted phenyl urea moiety was 
completely inactive. The 4-methyl and 4-ethyl derivatives 
were active at FPR2. In contrast, the sterically more demand-
ing 4-isopropyl analog lost activity. A more detailed survey 
of substituent changes at the phenyl urea moiety demon-
strated that the steric and electronic nature of the para-
substituent on the phenyl group had important effects on 
FPR2 agonist activity [98]. 
Modification of substituents at C(5) of pyrazolone ana-
logs revealed that the potency of compounds with bulkier 
substituents was consistently enhanced (Me<Et<i-Pr<t-Bu). 
As examples, structures and activities of compounds 13 and 
14 with i-Pr and t-Bu C(5)-substituents are shown in (Table 
2). Agonist 13 (designated in most of publications as “Com-
pound 43”) was rediscovered in independent HTS as a mixed 
FPR1/FPR2 agonist with EC50 ~4 nM at FPR2 [81]. This 
compound also induced a respiratory burst in mouse and 
human neutrophils and activated C3 receptor (CR3) mobili-
zation to the surface of human neutrophils [81, 91]. A substi-
tution of the pyrazolone core at N(2) position showed that 
modifications within this portion of the molecule were rela-
tively well tolerated. Indeed, the pyrimidines and quinolines 
were roughly equal or more potent than the corresponding 
phenyl derivatives, while thiazoles showed somewhat re-
duced activity [98]. 
 
Fig. (1). Panel A. Poses of agonists 1, 7, and 8 relative to the surface 
of the FPR1 binding site. Key sub-areas of the FPR1 binding site are 
indicated with arrows and include two channels (A and C), two cavi-
ties (B and E), and the bottom (D), as described previously [82]. Sur-
face coloring was made according to electrostatic properties, whereby 
negatively and positively charged areas are shown in red and blue, 
respectively. Panel B. Docking poses of benzimidazoles 7 (purple) 
and 8 (green) in FPR1. H-bonds are indicated with dashed lines. 
Table 1. Agonist Activity of Benzimidazoles 1-9 [79, 82] 
NH
O
S
N
NH
R1 R2
A
 
1-8 
NH
O
S
N
NH
O
O
O
 
9 
EC50 (?M)a 
# R1 R2 
FPR1 FPR2 PMN 
1 NO2 OCH3 3.4 N.A. 0.4 
2 OCH2CH3 OCH3 21.5 N.A. 5.8 
3 OCH3 OCH2CH3 19.1 N.A. 0.6 
4 OCH3 OCH3 1.7 5.1 0.3 
5 Cl OCH3 1.6 6.0 0.7 
6 Br OCH3 3.3 N.A. 1.8 
7 SCH3 OCH3 2.0 N.A. 0.5 
8 COOCH3 OCH3 1.5 N.A. 0.9 
9  2.2 N.A. 2.6 
aEC50 values were determined by measurement of Ca
2+ flux in FPR1- and FPR2-transfected HL-60 cells or in human polymorphonuclear neutrophils (PMN).  N.A., no activity ob-
served. 
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Although all 28 pyrazolone-derived FPR2 agonists were 
reported to have no FPR1 agonist activity up to a concentra-
tion of 10 μM [98], Sogawa et al. [99, 100] and Forsman et 
al. [91] demonstrated that pyrazolone 13 has dual FPR ago-
nist activity in HL-60 and CHO-K1 cells co-transfected with 
G?16 and FPR1/FPR2 and suggested that this discrepancy 
might be due to the different types of G-proteins used in the 
cell-based screening assays (G?16 vs. G?15) [99]. Indeed, 
compound 13 significantly inhibited the binding of 
[3H]fMLF and [125I]WKYMVM to FPR1 and FPR2, respec-
tively [100]. Moreover, the FPR1-specific antagonist cy-
closporine H completely abolished the neutrophil response to 
compound 13 [91]. Compound 13 had agonist activity for 
murine Fpr1 and Fpr2, with EC50 values of 0.35 and 0.89 
μM, respectively [100]. Using RBL-2H3 cells expressing 
mFpr1, mFpr2, and mFpr-rs1, He et al. [21] demonstrated 
that compound 13 induced Ca2+ mobilization and degranula-
tion via both mFpr1 and mFpr2, but not mFpr-rs1. This ago-
nist induced a rapid extracellular signal-regulated kinase 
(ERK) phosphorylation in murine peritoneal macrophages 
[101] and stimulated interleukin (IL)-6 secretion in 50% hu-
man blood [76]. Compound 13 also activated chemotactic 
responses in both human and mouse neutrophils, with a typi-
cal bell-shaped dose–response curve, and induced internali-
zation of both FPR1 and FPR2 [81, 99, 100]. 
The most potent pyrazolone FPR2 agonists 10 and 13 in-
hibited human neutrophil chemotaxis induced by fMLF and 
IL-8, probably via homo- and cross-desensitization [98]. 
Incubation of human neutrophils with compound 13 dimin-
ished the expression of C-X-C chemokine receptor types 1/2 
(CXCR1/2), complement receptor C5aR, and leukotriene B4 
(LTB4) receptor BLT1 [100]. Similarly, pretreatment with 
compound 13 dose-dependently inhibited Ca2+ flux and the 
chemotactic response of murine neutrophils stimulated with 
mouse C5a, LTB4, or keratinocyte chemoattractant (KC/ 
CXCL1), the murine homolog of human IL-8 [100, 102].  
Lead pyrazolones also demonstrated anti-inflammatory 
activity in vivo. Pyrazolone 10 caused reduction of ear 
edema in mice treated topically or orally prior to induction of 
edema [98]. Compound 13, administered i.v. prior to IL-1? 
injection into 6-day-old air pouches, produced 50–75% 
inhibition of cell recruitment in wild-type mice but were 
ineffective in Fpr2?/? animals [101]. In addition, compound 
13 inhibited neutrophil migration into the airway in LPS-
exposed mice, as well as zymosan-induced neutrophil accu-
mulation in the peritoneal cavity, possibly through cross-
desensitization [100]. 
3.3. N-Substituted Benzimidazoles 
In the next route of screening by researchers from Am-
gen, the N-substituted benzimidazole 15 was identified as an 
FPR2-specific agonist, and subsequent SAR studies identi-
fied 15 additional FPR2-specific agonists [76]. The authors 
found that benzimidazoles with small alkyl substituents, such 
as ethyl at C(2) (16), exhibited submicromolar FPR2 activity 
(Table 3), and further modification revealed that contraction 
of the piperidine ring in 16 to pyrrolidine R-enantiomer 17 
resulted in a 20-fold increase in potency. It should be noted 
that R-enantiomer 17 was significantly more potent than its 
S-counterpart 18 (Table 3). A brief survey centered around 
the nature of the C(5)-substituent in the indole fragment re-
vealed that OMe is optimal for FPR2 activity. Indeed, de-
rivatives with F, Cl, Br, O-CF3, and Et substituents at C(5) of 
the indole ring were less active than OMe in compound 17. 
The most potent N-substituted benzimidazole 17 inhibited 
human neutrophil chemotaxis induced by fMLF and IL-8, 
probably via cross-desensitization. In addition, compound 
17, in the presence of IL-1?, dose-dependently stimulated 
IL-6 secretion in 50% human blood above levels induced by 
IL-1? alone [76]. 
3.4. Pyridazin-3(2H)-ones 
In the past six years, our laboratories have been involved 
in the SAR directed design, synthesis, biological evaluation, 
and molecular modeling of pyridazin-3(2H)-ones with 
FPR1/FPR2 agonist activities. These aromatic compounds 
were screened using Ca2+ flux assay in FPR-transfected hu-
man promyelocytic leukemia HL-60 cells. By starting with 
Table 2. Agonist Activity of Pyrazolones 10-14 [98, 100] 
N
N
O
R1
NH NH
O
R2
 
EC50 (?M)a 
# R1 R2 
FPR1 FPR2 
10 CH3 I N.A. 0.03 
11 CH3 Br N.A. 0.09 
12 CH3 Cl N.A. 0.49 
13 i-Pr Cl N.A. 
(0.065)b 
0.044 
(0.022)b 
14 t-Bu Cl N.A. 0.023 
aEC50 values were determined by measurement of Ca
2+ flux in FPR1- and FPR2-transfected CHO cells; bEC50 values reported [100].  N.A., no activity observed. 
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the known pyrazolone scaffold [98] for FPR agonists (Table 
2), we first modified this scaffold but found that related pyri-
dazine derivatives failed to exhibit FPR agonist activity [78]. 
We next focused on analogues with a substituted benzyl 
group at position 4 of the pyridazinone moiety and a similar 
functionalized chain at N-2. This approach led to the identi-
fication of compound 19 with medium activity at FPR1/ 
FPR2 (Table 4). Thus this compound was selected as a lead, 
and extensive SAR studies were performed (Fig. 2). 
Table 3. Agonist Activity of N-substituted Benzimidazoles 15-
18 [76] 
EC50 (?M)a 
# Structure 
FPR1 FPR2 
15 
NH
O
N
O
N
NH
O  
N.A. 6.4 
16 
NH
O
N
O
N
NH
 
N.A. 0.69 
17 
NH
O
O
N
N
N
 
N.A. 0.034 
18 
NH
O
O
N
N
N
 
N.A. 3.5 
aEC50 values were determined by measurement of Ca
2+ flux in FPR1- and FPR2-
transfected CHO cells.  N.A., no activity observed. 
Elongation of the hydrocarbon chain at the acetamide 
spacer (e.g., compound 20) reduced potency at FPR1/FPR2 
(Table 4), and other modifications of the functionalized 
chain resulted in non-active compounds [78, 103]. However, 
introduction of different substituted aryl groups at the nitro-
gen atom of the acetamide fragment was more successful. 
Among compounds with a halogen-substituted phenyl ring, 
the 4-Cl and 4-I analogues exhibited the same profile as the 
4-Br substituted compound (19), but the 4-F derivative was 
specific for FPR1. In contrast, moving Br to positions meta 
or ortho resulted in a complete loss of FPR1/FPR2 activity. 
The elimination or replacement of 4-Br with substituents 
having similar steric properties, such as t-Bu, OCF3, and CN 
also led to loss of FPR agonist activity. The 4-
trifluoromethyl, the 4-nitro, 4-methyl, 4-methoxy, and 3,4-
dimethoxy analogues had relatively low activity at 
FPR1/FPR2, whereas the 3,4-methylendioxy derivative 21 
was specific for FPR1.  
The methyl group at position C-6 of the pyridazinone 
ring was modified to introduce a cyclohexyl group, a 2-
thienyl group, (substituted)aryl groups, and a benzyl group. 
None of these modifications led to more active FPR1/FPR2 
agonist compared to reference compound 19 [104]. SAR 
analysis based on substituents at position C-4 of the pyridaz-
inone scaffold was also performed [104]. Moving OCH3 
from the meta to the para position resulted in compound 22, 
an FPR2-selective agonist. Substitution of OCH3 in com-
pound 22 with SCH3 resulted loss of activity for all FPRs 
[103]. Introduction of fluorine in the meta position gave 
compound 23, which was an FPR1-specific agonist, and a 
similar selective activity was evident for its chloro-analogue. 
Replacement of the methoxyphenyl group in compound 19 
with 5- and 6-membered heterocycles (e.g., compound 24), 
including 3-furyl, 3-thienyl, 2-thienyl, and 3-pyridyl groups 
resulted in mixed FPR1/FPR2 agonists. Introduction of a 
carbonyl group as spacer in place of CH2 in the benzyl group 
at position C-4 resulted in compound 25, which is a rela-
tively potent mixed FPR1/FPR2 agonist. Substitution of CH2 
with an amidic group was detrimental for FPR1, but not 
FPR2 activity (compound 26). In addition, compounds 19-26 
also activated Ca2+ mobilization and chemotaxis in human 
neutrophils [78, 104].  
Taken together, SAR analysis suggested that the position 
C-6 of the pyridazinone ring was not readily tolerant to 
modifications. In contrast, position C-4 was more amenable 
to chemical manipulation. Indeed, substituted benzyl groups 
and heterocycles, as well as functionalized spacers (e.g., CO, 
NH), can be productively introduced at this level, retaining 
good agonist activity. Regarding the substituted phenyl ring 
attached to the acetamide fragment, the presence of a lipo-
philic and/or electronegative substituent, such as F, Br, Cl or 
CH3, in the para position is an essential requirement for 
FPR1/FPR2 agonist activity. Likewise, the presence of an 
acetamide spacer at pyridazine N-2 also plays a critical role 
in specificity and potency. The optimal length of the spacer 
is four chemical bonds. The importance of both CO and NH 
in the spacer seems to indicate that a H-bond donor neigh-
boring a H-bond acceptor system is also an essential re-
quirement for binding at FPRs. This is consistent with the 
structures of other reported FPR1/FPR2 agonists, where the 
presence of an urea is a common structural element. Moreo-
ver, this H-bond donor/acceptor system must be placed at an 
appropriate distance from both the aromatic and the hetero-
cyclic scaffold (see below). 
3.4.1. Molecular Docking of Pyridazin-3(2H)-ones 
Molecular docking of selected pyridazin-3(2H)-ones into 
the binding sites of FPR1 and FPR2 was performed in order 
to evaluate how the presence of different substituents and 
atoms influences the binding modes of the molecules [103, 
104]. Molecular skeletons within the binding site of FPR1 
were located mainly along cavity B and directed to channels 
A and C or to cavity E, in accordance with binding modes 
for 2-arylacetamide pyridazin-3(2H)-ones (Figs. 1A and 3A).
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Table 4. Agonist Activity of Pyridazin-3(2H)-ones 19-26 [78, 103, 104] 
EC50 (?M)a 
# Structure 
FPR1 FPR2 PMN 
19 
N
N
O
NH
O
Br
O
 
3.4 3.8 2.6 
20 
N
N
O
O
NH
O
Br
 
9.7 5.4 11.3 
21 
N
N
O
O NH
O
O
O
 
2.3 NA 3.2 
22 
N
N
NH
O
O
BrO
 
N.A. 2.4 4.3 
23 
N
N
NH
O
O
Br
F
 
6.6 N.A. 4.2 
24 
N
N
N
NH
O
O
Br
 
9.3 2.8 4.9 
25 
O
N
N
NH
O
O
Br
O  
3.0 1.0 2.3 
26 
NH N
N
NH
O
O
Br
O
O
 
9.3 2.8 2.4 
aEC50 values were determined by measurement of Ca
2+ flux in FPR1- and FPR2-transfected HL-60 cells or in human polymorphonuclear neutrophils (PMN).  N.A., no activity ob-
served. 
Noticeably, bromine-substituted compounds, in their best 
poses, had bulky and highly hydrophobic p-bromophenyl 
groups located in the vicinity of channel A and directed out-
side the binding site (for example, see overlapped docking 
poses of fMLF and compound 23 in Fig. 3A). Additionally, 
H-bonding interactions of Thr265 with the pyridazine nitro-
gen atom are evident in agonists 19 and 25, as are interac-
tions with the carbonyl group of the pyridazinone moiety in 
compound 24 (Fig. 3B). For compound 25, this carbonyl is 
also H-bonded to both Thr199 and Asn192. Compound 21, 
which contains a benzodioxolane moiety instead of a p-
bromophenyl group, had the opposite binding mode, with the 
benzodioxolane protruding into channel C. In its docking 
pose, this compound formed a H-bond between one of its 
endocyclic oxygen atoms and the hydroxyl group of Tyr257 
(Fig. 3C). 
The FPR2 model was constructed by homology modeling 
using the Phyre2 server. The rhodopsin-based model of FPR2 
was selected as the most predictive structure from 18 other 
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homology models based on 8 dissolved crystal structures of 
GPCRs [105]. Although the CXCR4 structure has a higher 
sequence identity with FPR2 (28%), this structure has a low 
resolution (3.2 Å) for the template, as compared to the 
rhodopsin structure (2.2 Å). The ligand binding site of FPR2 
has a non-symmetric dumb-bell shape with two cavities dif-
ferent in size, where the smaller cavity lies deeply in the bind-
ing site and is surrounded by residues Val105, Asp106, 
Leu109, Phe110, Arg201, Trp254, and Gln258 [105]. FPR2-
specific peptide agonist WKYMVM in its best docking pose 
occupies this cavity with an indole moiety near the N-terminus 
of the peptide. A narrow channel connecting the two cavities 
is bordered by residues Phe257, Val260, Ala261, Thr177, 
Phe178, and Phe180. The larger cavity of the docking site 
opens outside the receptor and has a complex shape. 
 
Fig. (2). SAR directed design of FPR agonists with pyridazin-
3(2H)-one scaffold. 
Docking of FPR2 agonists 19, 22, and 24-26 to FPR2 
showed that they adopt conformations that overlap well with 
the docking pose of WKYMVM. Characteristically, the 
bromo-substituted phenyl rings of these molecules lie within 
the smaller cavity found deep within the binding site (Fig. 
4A). The narrow channel contains an amide fragment adja-
cent to the p-bromophenyl groups of the molecules. In addi-
tion, the pyridazinone moieties are oriented similarly in the 
binding site with their carbonyl and methyl groups overlaid 
in the same positions. Such an orientation is conditioned by 
the possibility of H-bonding of the nitrogen atom in the pyri-
dazine ring, as well as an oxygen or nitrogen atom in the 
amide moiety, with the hydroxyl group of Thr177. As an 
example, specific interactions of agonist 25 with Thr177 and 
Ala261 are shown in (Fig. 4B).  
As discussed above, Arg205 is one of the key residues im-
portant for FPR1 agonist activity [82, 96]. Indeed, active pyri-
dazinone 19 forms a H-bond with Arg205 in FPR1, with total 
interaction energy of 32.9 kcal/mol with this residue. How-
ever, the sulfur-containing analogue with a thio-acetamide 
fragment had a much weaker non-bonded attractive interaction 
with Arg205 (8.82 kcal/mol). Another thio-analogue of com-
pound 22 containing a p-methylthio group instead of the p-
methoxy substituent was not H-bonded to any FPR1 residue 
[103]. Docking studies with the FPR2 homology model 
showed that the binding modes of oxygen-containing deriva-
tives were also quite different from their thio-analogues [103]. 
The inactive sulfur-containing derivatives contain bulky 
groups that extend outside the cavity, which caused steric hin-
drance and prevented effective binding of the ligands with 
FPR2. Hence, these molecules cannot adopt the more suitable 
conformations that are possible for the corresponding oxygen-
containing derivatives. For example, the best docking pose of 
the p-methylthio analogue of compound 22 had significant 
repulsive interactions with Tyr277 and Ile280 of FPR2. De-
spite H-bonding with Asn171 and Asp173, this docking pose 
was energetically unfavorable, as compared to that of the ac-
tive methoxy-derivative 22. For the best pose of compound 22, 
the closest non-valent contact of 2.48 Å occurs between the 
methoxy oxygen atom in molecule 22 and Thr168. An analo-
gous pose would be impossible for the corresponding com-
pound with a p-methylthio group, which is more bulky than 
the methoxy substituent. 
3.5. Chiral Pyridazines 
Based on the pyridazine-3(2H)-one scaffold, two series 
of chiral derivatives were synthesized and evaluated [77, 
106]. While we found that orientation of the chiral C5-
methyl substituent in N-(4-bromophenyl)-2-[5-methyl-6-oxo-
3-phenyl-5,6-dihydropyridazin-1(4H)-yl]acetamide and its 
analogues had little effect on agonist activity, orientation of 
the chiral center attached to nitrogen atom in position 2 of 
pyridazinone heterocycle had significant effects [77]. For 
these compounds, the S-(+) enantiomers lacked FPR agonist 
activity, whereas the R-(-) counterparts 27-29 had high activ-
ity in the micromolar or even nanomolar range (Table 5). In 
general, elongation of the carbon chain at the chiral center in 
R-enantiomers increased agonist activity (CH3<C2H5=n-
C3H7<n-C4H9=C6H5) at FPR1/FPR2, suggesting the impor-
tance of considering this molecular feature in further devel-
opment of these analogues. 
3.6. N-Phenylurea Derivatives 
HTS of a large chemolibrary resulted in the identification 
of FPR2-specific agonist 30 with an N´-phenylurea scaffold 
[75]. This compound activated reactive oxygen species 
(ROS) production by murine neutrophils and induced Ca2+ 
mobilization and chemotaxis in human neutrophils [79]. 
SAR analysis of related derivatives revealed three additional 
FPR2-specific agonists 31-33 (Table 6). All active 
derivatives contained a para methoxy group in benzene ring 
B, which seems to be an essential feature for activity of these 
derivatives. However, introduction of additional methoxy 
groups to ring B resulted in total loss of activity. Most active 
derivatives contained a halogen atom in the para position of 
benzene ring A. However, the presence of the halogen atom 
was not absolutely essential for biological activity, as 
compound 31 was also an active FPR2 agonist. Moving the 
halogen atom from the para position to the meta and then 
ortho positions resulted in decreased or completely lost 
activity, respectively. 
Branching of the hydrocarbon chain in N-phenyl-N’-(2-
phenylethyl)urea derivatives resulted in a series of analogs 
with a chiral sp3 carbon near the carbamide nitrogen atom. 
The resulting benzyl-containing moiety is structurally related 
to the phenylalanine derivatives. Our screening demonstrated 
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that nine Phe-based analogs and nine other related analogs 
were potent FPR agonists [80], and structures of selected 
compounds 34-47 are shown in (Tables 7 and 8). Although 
most of the compounds were mixed FPR1/FPR2 agonists, 
many displayed much higher selectivity for FPR2. It should 
be noted, that both enantiomers of racemic mixture 35 were 
reported previously in independent screenings as FPR2 
agonists Acadia C5 and Acadia C6 [45], and their reported 
EC50 at this receptor was ~30-35 nM [81], which is pretty 
close to the racemic mixture (Table 7). The S-enantiomer has 
been shown to dose-dependently prevent hyperalgesia 
induced by carrageenan in rats [45]. 
 
Fig. (3). Panel A. Docking poses of fMLF (atoms are highlighted 
by green spheres) and pyridazin-3(2H)-one 23 (atoms are not high-
lighted). Key sub-areas of the FPR1 binding site are indicated with 
arrows as in (Fig. 1B). Panel B. Interactions between Thr265 of 
FPR1 and molecule 24. H-bond is indicated with a dashed line. 
Panel C. Specific interaction between Tyr257 of FPR1 and com-
pound 21. H-bond is indicated with a dashed line. 
 
Fig. (4). Panel A. Overlapping docking poses of WKYMVM (at-
oms are indicated with green spheres) and pyridazin-3(2H)-ones 19, 
22, and 24-26. FPR2 residues within 6 Å around the smaller cavity 
are shown. Panel B. Compound 25 docked into the FPR2 binding 
site. Residues lying within 3.5 Å of the pose are shown. H-bonds 
are indicated with dashed lines. 
Table 5. Agonist Activity of Chiral Pyridazin-3(2H)-ones 27-
29 [77] 
O
N
N
O R
NH
O
Br
 
EC50 (μM)a 
# R 
FPR1 FPR2 PMN 
27 n-C3H7 3.0 0.84 0.93 
28 i-C3H7 9.4 5.4 2.3 
29 n-C4H9 0.5 0.089 0.073 
aEC50 values were determined by measurement of Ca
2+ flux in FPR1- and FPR2-
transfected HL-60 cells or in human polymorphonuclear neutrophils (PMN). 
3.7. Chiral 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido] 
propanamides 
Screening of a small library of 32 low-molecular-weight 
ligands of 24 different GPCRs led to the identification of two 
bombesin receptor BB1/BB2 antagonists, PD176252 (com-
pound 48) and PD168368 (compound 49), as potent mixed 
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FPR1/FPR2 agonists [80]. Although several potent FPR1/ 
FPR2 agonists were found through secondary screening of 
Trp-based analogs from commercial chemical libraries, 
subsequent SAR analysis was completed by synthesis of 
related enantiomers using stereospecific methods starting 
from the enantiomerically pure N-Boc-R-Trp or N-Boc-S-
Trp [105]. From this approach, several potent FPR agonists, 
including FPR2-specific agonists 50-53, were identified. 
Unexpectedly, the majority of compounds found to induce 
Ca2+ mobilization in FPR-transfected HL-60 cells failed to 
stimulate this response in human neutrophils. This finding is 
supported by our previous findings that some chiral FPR 
agonists and their closely related achiral derivatives are 
much (up to 600-fold) less active for activation of Ca2+ mo-
bilization in human neutrophils than in the FPR-transfected 
cells [80]. Pretreatment of human neutrophils with pro-
benecid restored the Ca2+ flux response in neutrophils treated 
with most of these derivatives. Structures of selected FPR 
agonists 48-53 are shown in (Table 9). Because substitution 
of OCH3, CF3, Br, and CH3 in the para position of the 
phenyl ring with CN or NO2 and removing CH3 at the chiral 
center of compounds 48 and 49 resulted in loss of ability to 
activate neutrophil Ca2+ flux without probenecid pretreat-
ment, it appears that the requirement for probenecid is some-
how related to compound structure. We suggest that com-
pounds 48 and 49 have more flexible structures than the par-
ent compounds, where an intramolecular H-bond between an 
amino group and the carbamide carbonyl atom could signifi-
cantly restrict conformational freedom of these molecules. 
Thus, increased flexibility of the chiral agonists could be 
analogous to conformation changes in FPR2 [105]. Alterna-
tively, because OCH3, CF3, Br, and CH3 in the para-position 
of the phenyl ring of FPR2 agonists are less electronegative 
than NO2 and CN groups [107], potency of electrostatic and 
H-bond interactions in FPR2 subpockets could be an impor-
tant characteristic for activation of G-protein coupling and 
Ca2+ flux in human neutrophils. 
Table 6. Agonist Activity of N-phenylurea Derivatives 30-33 
[75, 79] 
R
NH NH
O
O
A B
 
EC50 (?M)a 
# R 
FPR1 FPR2 PMN 
30 Cl N.A. 0.4 0.7 
31 H N.A. 3.0 4.8 
32 F N.A. 0.9 1.2 
33 Br N.A. 0.1 1.2 
aEC50 values were determined by measurement of Ca
2+ flux in FPR1- and FPR2-
transfected HL-60 cells or in human polymorphonuclear neutrophils (PMN).  N.A., no 
activity observed. 
Analysis of the literature indicates that probenecid is a 
non-specific inhibitor of multidrug resistance-associated pro-
teins and can have different effects on several other cellular 
targets. For example, probenecid is able to activate transient 
receptor potential V2 (TRPV2), Ca2+-permeable nonselective 
cation channel [108], and transient receptor potential channel 
subtype A member 1 (TRPA1), another nonselective cation 
channel [109], and it has recently been reported that pro-
benecid can directly modulate interaction of GPCR and G-
proteins [110]. In addition, Prossnitz et al. [111] proposed that 
primary myeloid cells maintain a subpopulation of FPR in a 
low-affinity, possibly G protein-free state, which is not a fea-
ture of FPR-transfected HL-60 cells. Because allosteric com-
munication between the ligand-binding orthosteric site and the 
cytoplasmic G-protein-binding surface is a fundamental fea-
ture of GPCRs [112], it is possible that certain FPR2 agonists, 
such as the ureidopropanamides 50-53, could stabilize this 
receptor in a G-protein-free state, and additional agents (e.g., 
probenecid) may be required to reactivate G-protein coupling. 
Table 7. Agonist Activity of Chiral N-phenylurea Derivatives 
34-38 [80] 
Br
NH NH
O
R O
*
 
EC50 (?M)a 
# R 
FPR1 FPR2 FPR3 PMN 
34 
N
 
4.5 0.14 11.5 3.2 
35 
N
 
1.8 0.04 6.5 1.2 
36 
NH
NH
O  
0.3 0.004 0.1 0.7 
37 
N O
O
 
0.08 0.007 0.5 0.5 
38 
O
O
N
 
N.A. 0.16 N.A. 4.4 
aEC50 values were determined by measurement of Ca
2+ flux in FPR1-, FPR2-, and 
FPR3-transfected  
HL-60 cells or in human polymorphonuclear neutrophils (PMN).  N.A., no activity 
observed. 
3.8. Molecular Modeling of Chiral Recognition at FPR2 
To investigate the enantiomer preference observed for FPR2 
agonists with different scaffolds and chiral center substituents, 
we created a pharmacophore model for FPR2 using field point 
methodology [113-115] based on five potent small-molecule 
non-peptide FPR2 agonists, including FPR agonist 42 and four 
chiral molecules (both S- and R- forms) 17, 35, 36, and 49 [80]. 
The hydrophobic field surface of the 5-molecule FPR2 template 
consists of three regions (H1, H2, and H3), which correlate with 
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subpockets I, II, and III in the FPR2 binding site, respectively 
(Fig. 5). FPR2 agonists and their inactive enantiomers were 
overlaid in the three-subpocket model. The similarity values 
depend equally on geometric and field similarity of a molecule 
and template. For most chiral pyridazin-3(2H)-ones [77], the 
similarity between aligned molecule and the template for R-
enantiomers was higher than that of their S-enantiomer counter-
parts. Moreover, more active enantiomers with a ureidopro-
panamide scaffold had better alignments than the corresponding 
inactive enantiomers [105]. A visual inspection of the molecule 
overlays on the 5-molecule FPR2 template showed that in most 
cases the active enantiomers had alignment modes with non-
polar molecular fragments located in subpocket II, while 
bromo- or nitro-substituted phenyl rings were always positioned 
in subpocket I. In particular, moieties without polar atoms occu-
pied subpocket II, while polar substructures (methoxy in ben-
zene rings or indole NH groups) were located in subpocket III 
for these alignments [105]. 
Table 8. Agonist Activity of Benzodioxole Derivatives of N-
phenylureas 39-47 [80] 
NH NH
O
R
O
O O
O
 
39-43 
NH NH
O
R1
O
O
R2
*
 
44-47 
EC50 (μM)a 
# R 
FPR1 FPR2 FPR3 PMN 
39 H N.A. 0.006 3.3 5.9  
40 F 1.7 0.004 0.7 0.7 
41 Cl 3.7 0.002 0.2 0.06 
42 Br 2.7 0.004 1.7 0.1 
43 Me 5.1 0.07 10.8 4.5 
 
EC50 (μM)a 
# R1 R2 
FPR1 FPR2 FPR3 PMN 
44 H F N.A. 0.12 1.3 1.2 
45 F F 7.5 0.02 1.2 0.14 
46 Me F N.A. 0.5 N.A. 10.1 
47 Cl O-Me 0.11 0.0002 0.05 0.013 
aEC50 values were determined by measurement of Ca
2+ flux in FPR1-, FPR2-, and 
FPR3-transfected  
HL-60 cells or in human polymorphonuclear neutrophils (PMN).  N.A., no activity 
observed. 
According to docking studies with the FPR2 homology 
model [105], the pharmacophore subpocket I is surrounded 
by His102, Val105, Asp106, Leu109, Trp254, Phe257, 
Ser288, and Phe292 and lies in the smaller cavity. Residues 
His102, Val105, Asp106, Leu109, and Trp254 were also 
identified by Fujita et al. [116] as critical for the FPR2 bind-
ing site. Residues surrounding subpockets II and III were 
also identified [105]. The FPR2-specific peptide agonist 
WKYMVM, in its best docking pose, occupies all three sub-
pockets, with the N-terminal indole moiety located in sub-
pocket I. Subsequent modeling with FPR agonists showed 
that the geometric configuration of the FPR2 binding site fits 
well with the shape of the hydrophobic field obtained for the 
FPR2 agonist pharmacophore model, and extrema of nega-
tive and positive fields correspond well to areas of the ligand 
binding site of the FPR2 homology model (Fig. 5). Thus, this 
correspondence seems to be important for proper orientation 
of an agonist molecule for penetration into the binding site. 
3.9. 2-(N-Piperazinyl)acetamide Derivatives 
Eight FPR2-specific agonists 54-61 with a 2-(N-
piperazinyl)acetamide scaffold were discovered while 
screening a chemical library using the Ca2+ flux assay in 
FPR1/FPR2 RBL cells as readout (Table 10). All active de-
rivatives contained Br in the para position of benzene ring 
A, which was required for activity. Furthermore, moving Br 
from the para position to the ortho or meta positions resulted 
in loss of activity. Finally, replacement of para Br in ring A 
with a variety of other substituents resulted in loss of activity 
[79]. It is noteworthy that related piperazines were reported 
as selective agonists of the dopamine D4 receptor, which is 
also a GPCR [117]. Whether our FPR2 agonists are also D4 
receptor agonists has not been evaluated.  
3.10. Quinazolinones 
Quinazolinone 62 (designated in most of publications as 
Quin-C1) was described as one of first small-molecule non-
peptide FPR agonists [74]. This compound selectively acti-
vated FPR2 vs. FPR1 (EC50 ~1.4 ?M), induced ROS produc-
tion, degranulation, and chemotaxis in human neutrophils 
and stimulated internalization of FPR2 and ERK phosphory-
lation [74, 81]. Compound 62 activated both mFpr1/mFpr2 
[21] and demonstrated anti-inflammatory properties in a 
mouse model of lung injury [118]. Furthermore, HTS and 
SAR-directed design and synthesis identified analogs 63-66 
[79, 119], including FPR2-specific agonists containing 
methyl (63), nitro (64), and 3,4-methylenedioxy (66) groups 
in the para-position of benzene ring A (Table 11). Substitu-
tion with bulky groups, such as isobutoxy or butoxy, at this 
position resulted in loss of agonist activity, and activity was 
also lost when the nitro group in compound 64 was changed 
to amino or dimethylamino groups. Elimination of the 
methoxy group in compound 62 or introduction of an addi-
tional methoxy group in the meta position of 62 also resulted 
in inactive compounds [119]. Our recent screening identified 
related quinazolinone 65 as a potent FPR agonist [79].  
3.11. Miscellaneous FPR Agonists 
Structures of FPR agonists with varying scaffolds but 
with no clear SAR emerging from evaluation of their analogs
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Table 9. Agonist Activity of Chiral 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamides 48-53 [105] 
NH NH
O
NH
O
NH
N
O
N+
O-
O
 
48 (PD176252) 
NH NH
O
NH
O
NH
N
N+
O-
O
 
49 (PD168368) 
NH
NH
O
NH
O
NH
N+
O-
O
N
O
 
50 
NH
NH
O
NH
O
NH
N+
O-
O
 
51 
NH
NH
O
NH
O
NH
N
N
O
 
52 
NH
NH
O
NH
O
NH
N+
O-
O
N
 
53 
 
EC50 (?M)a 
PMN
 # 
FPR1 FPR2 
w/o Prob. with Prob. 
48 0.33 1.3 0.72 0.21 
49 0.57 0.62 0.91 0.19 
50 N.A. 0.023 N.A. 0.0032 
51 N.A. 0.7 N.A. 0.05 
52 N.A. 0.36 N.A. 0.022 
53 N.A. 0.19 N.A. 0.46 
aEC50 values were determined by measurement of Ca
2+ flux in FPR1- and FPR2-transfected HL-60 cells or in human polymorphonuclear neutrophils (PMN) analyzed without (w/o) or 
in the presence of 2.5 mM probenecid (Prob.).  N.A., no activity observed. 
are discussed here (Table 12). Five acetohydrazides, includ-
ing chiral compound 67, dibenzoylhydrazine 68, and thienyl-
pentanamide 69 were identified as FPR2-specific agonists in 
library screening [79]. Derivatives of 2-(indol-3-yl)-1,3-
thiazolidin-4-one 70, N,N´-diphenylurea 71, and (3-
thienyl)methylene acetylhydrazide 72 were found to be 
mixed FPR1/FPR2 agonists, and compounds 68-72 activated 
chemotaxis in human neutrophils [79]. Two other phenyl-
substituted ureas 73 and 74 have been reported as potent 
FPR2-specific agonists [81]. Compounds 75 and 76 [81] are 
unique from other described FPR agonists because these 
compounds have carboxyl/hydroxyl groups. It should be 
noted that compounds 75 and 76 activated intracellular Ca2+ 
mobilization in CHO cells expressing FPR1 as well as FPR2, 
but the EC50 for FPR1 agonist activity was not reported [81]. 
Compound 77, with a unique 2-(4-phenyl-5-((phenylamino) 
methyl)-1,2,4-triazol-3-ylthio)acetamide scaffold, and its 
closely related derivatives were patented as the first small-
molecule non-peptide FPR2 agonists, but their activities 
(EC50 values) at this receptor were not reported [45]. 
Compound 77 was further rediscovered in independent 
screening as a potent FPR2-specific agonist with nanomolar 
activity [81]. Compounds 78 [81] and 79 [120] each have 
identical groups at the sp3 carbon atom, resembling struc-
tures of other FPR agonists 39-43 [80]. It should be noted, 
that the low activity FPR1 agonist 79 was found using com-
puter-aided prioritization and subsequent physical screening 
[120]. 
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Fig. (5). Model of chiral compound docking to FPR2. Geometry of 
the hydrophobic field surface of the pharmacophore model matches 
to the binding site geometry of FPR2. An FPR2 agonist can ap-
proach the FPR2 binding site from the top (“mouth”) of the cavity, 
shown by dashed yellow line around the agonist template (hydro-
phobic regions H2 and H3) and around the cavity mouth, which 
includes subpockets II and III. Field points are colored as follows: 
blue, electron-rich (negative); red, electron-deficient (positive); 
yellow, van der Waals attractive (steric). Hydrophobic region H1 
(usually associated with 4-nitrophenyl or 4-bromophenyl groups in 
FPR2 agonists) should properly fit into subpocket I of the FPR2 
ligand-binding site. The cavity of the FPR2 binding site shows the 
position of side chain tails of compound 53 in subpockets II and III. 
Surface coloring was made according to electrostatic properties, 
whereby negatively and positively charged areas are shown in red 
and blue, respectively. It should be noted, that blue (positively 
charged) surface areas of the receptor correspond to blue field 
points obtained with positive probe atom and red (negatively 
charged) surface areas of the receptor correspond to red field points 
obtained with negative probe atom. Areas of subpockets are indi-
cated with light-blue arrows. Numeration of subpockets and the 
hydrophobic surface of the FPR2 pharmacophore model are as re-
ported in [80, 105]. 
Compounds 80-82 containing an arylcarboxylic acid hy-
drazide core structure potently induced TNF production in 
macrophages, presumably via FPR activation [121, 122]. 
Compound 80 is an FPR1-specific agonist, whereas com-
pounds 81 and 82 are low activity FPR2-specific agonists 
(Table 12). Compounds 80-82 stimulated intracellular Ca2+ 
mobilization, chemotaxis, and ROS production in murine 
and human neutrophils [75, 121]. Currently, compound 80 is 
sold by Tocris Bioscience as an FPR1 agonist designated as 
FPRA14. 
Recently, polyphenylure 83 and pyrrolidine bis-
diketopiperazine 84 were found to be specific high-affinity 
FPR1 and FPR2 agonists, respectively, using mixture-based 
combinatorial libraries [123]. However, activity of these 
potent agonists in neutrophils was not evaluated. 
Two non-peptide calpain inhibitors that are ?-mercapto-
acrylic acid derivatives, PD150606 (compound 85) and 
PD151746 (compound 86), were reported to induce Ca2+ 
mobilization in FPR2-transfected HEK-293 cells [116, 124]. 
These compounds have atypical chemical structures, as 
compared with most reported FPR agonists. Indeed, a visual 
inspection of molecules 1-84 shows that a typical FPR ago-
nist contains at least two heterocycles separated by a chemi-
cal linker with >2 bonds (see also [79]). We evaluated ability 
of the calpain inhibitors 85 and 86 to stimulate Ca2+ mobili-
zation in FPR1/FPR2 transfected HL-60 cells, but both com-
pounds were inactive in our hands at concentrations up to 30 
?M (unpublished data). The explanation for this discrepancy 
might be due to the different types of G-proteins used in the 
cell-based screening assays. Although docking simulations 
demonstrated several low-energy poses of compound 85 in 
the orthosteric binding site of FPR2 [116], pepducin-like 
allosteric interaction of these calpain inhibitors with allos-
teric sites, including the FPR2–G-protein interface, or even 
direct effects on G-proteins could not be excluded.  
Two methionine-derived benzimidazoles were recently 
identified as neutrophil agonists in a Ca2+ mobilization assay 
by Unitt et al. [84] during HTS and subsequent SAR analysis 
[84]. However, FPR subtype specificity for these compounds 
was not reported.  
4. SMALL-MOLECULE FPR ANTAGONISTS AND 
THEIR MODELING 
4.1. Diamides 
Using HTS for compound inhibition of Alexa647-labeled 
fMLFK-specific binding to HEL-293 cells expressing FPR1 
and G?16 and subsequent analysis for inhibition of fMLF-
stimulated intracellular Ca2+ mobilization in human neutro-
phils, Unitt et al. [84] identified diamide 87, which antago-
nized FPR1 function in human neutrophils (Table 13). The 
most potent diamide analog identified (compound 88) pos-
sessed a more lipophilic substitent R, as compared to com-
pounds 89-92, which contain 4-chlorophenyl, benzyl, cyclo-
hexyl, and 1-methylimidazolyl substituents, respectively. For 
the benzoyl moiety, an ortho hydroxy group was essential to 
maintain FPR1 antagonist activity, and replacing the hy-
droxyl in compound 89 with OCH3 or CH3 led to inactive 
compounds. In addition, the nature of the antagonism exhib-
ited by these diamides (i.e., competitive vs. non-competitive) 
was not evaluated. Initial SAR for the diamides and several 
of their analogs suggested that in order to generate a good 
FPR1 antagonist profile, compounds would require a number 
of parameters that would be challenging to successfully 
modify in latter phases of drug development. As result, fur-
ther work, including testing enantiomers, was not undertaken 
[84].  
4.2. Methionine-derived Benzimidazoles 
Another FPR1 antagonist discovered by Unitt et al. [84] 
was the methionine-derived benzimidazole 93 (Table 14). 
Compound 93 demonstrated low antagonism at rat Fpr1 
(IC50 = 10 ?M), but was inactive at mouse Fpr1. Modifica-
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tion of the benzofuran group in 93, including removal of the 
ethoxy group (compound 94) or fused benzene ring (com-
pound 95), reduced activity. Compound 96, with a cyclo-
hexyl moiety, was more active in comparison with com-
pound 97, which contained a phenyl substituent. Derivative 
98 with a 3-chloro-2-thienyl group was very close in activity 
to cyclohexyl-containing compound 96. Modification of the 
benzimidazole group by introduction of a benzyl group re-
duced activity (compound 99), although subsequent intro-
duction of a cyano group in the para position of the benzyl 
moiety increased antagonist activity (compound 100). Incor-
poration of heteroatoms into the phenyl ring of the benzimi-
dazole had variable effects, depending on the substitution 
pattern. Purine (compound 101) and 4-azabenzimidazole 
(compound 102) derivatives were less active than reference 
compound 93. Moreover, substitution of the benzimidazole 
group in compound 93 with 5-azabenzimidazole led to the 
appearance of FPR agonist activity, although FPR subtype 
specificity for this compound was not reported. S-enantiomer 
103 with an ethylthiomethyl group was equiactive to com-
pound 93, although its R-counterpart 104 had a lower an-
tagonistic activity. 
4.3. Pyrazole-4-carboxamides 
A series of pyrazole-based FPR1 antagonists have been 
identified from HTS and subsequent optimization [86, 87] 
(Table 15). Compound 105 was first identified by HTS [87], 
although attempts to obtain more potent antagonists by 
modification or replacement of the sulphonamide and amide 
motif were unsuccessful, suggesting that the amidic group is 
necessary for FPR1 agonist activity. However, conforma-
tional effects of these changes cannot be excluded. Introduc-
tion of a methyl substituent at the 3 position of the pyrazole 
scaffold resulted in a modest increase in potency (compound 
105 vs. 106), and modification of the carboxamide moiety 
led to S-enantiomer 107, which was preferentially active 
over the R-counterpart 108 by ~6-fold. Introduction of 
strongly electron-withdrawing fluorine and cyano groups 
into both phenyl rings of the S-enantiomer led to compound 
109, which possessed a substantially higher antagonist activ-
ity than the initial pyrazole 107. During subsequent optimi-
zation, the alkyl pyrazole substituent was varied in com-
pound 107, with the most potent analogs 110-112 bearing 
cyclohexyl, tetrahydrothiopyran-4-yl, and 4-methoxycyclo- 
hexyl groups, respectively [86]. It is interesting to note that 
the trans-diastereoisomer of compound 112 was completely 
inactive, highlighting specificity of the interaction of the 
methoxy motif with FPR1. Compound 112 has good phar-
macokinetic properties and is the most potent FPR1 antago-
nist among the known synthetic small-molecule FPR an-
tagonists. Note, however, that the nature of the antagonist 
activity (i.e., competitive vs. non-competitive) was not evalu-
ated for these methionine-derived benzimidazoles and 
pyrazole-4-carboxamides, so allosteric inhibition cannot be 
excluded.  
4.4. Miscellaneous FPR Antagonists 
Sulfinpyrazone 113 (Table 16) and its related derivative 
1,2-diphenyl-4-(3-(1-naphthyl)-propyl)-3,5-pyrazolidinedione 
(DNP) were reported as the first competitive FPR1 antago-
nists [125, 126]. The low affinity of sulfinpyrazone at FPR1 
(Ki=14 ?M) was later supported by Young et al. [127]. It 
should be noted that sulfinpyrazone is a non-steroidal anti-
inflammatory drug (NSAID) that alters platelet function by 
inhibiting cyclooxygenase activity [128]. In addition, this 
drug acts as a general inhibitor of organic anion transporters 
[129]. Other NSAIDs, including diclofenac, piroxicam 
(compound 114), and its close analog tenoxicam were found 
Table 10. Agonist Activity of 2-(N-piperazinyl)acetamides 54-61 [79] 
NH
O
N
N
R4
R3
Br R2
R1
A
 
EC50 (?M)a 
# R1 R2 R3 R4 
FPR1 FPR2 PMN 
54 H H F H N.A. 19.3 10.5 
55 H Cl H H N.A. 15.1 16.4 
56 H H H H N.A. 8.7 2.3 
57 H H Cl H N.A. 2.1 2.0 
58 H Cl CH3 H N.A. 4.3 1.0 
59 CH3 Cl H H N.A. 4.1 1.8 
60 CH3 H H Cl N.A. 9.4 0.4 
61 H OCH3 H H N.A. 11.0 7.9 
aEC50 values were determined by measurement of Ca
2+ flux in FPR1- and FPR2-transfected RBL cells or in human polymorphonuclear neutrophils (PMN).  N.A., no activity ob-
served. 
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to be low activity FPR1 antagonists [130, 131]. Losartan, a 
selective antagonist of AT1 receptor activation by angio-
tensin II and sulfasalazine, a drug useful in the therapy of 
inflammatory bowel disease [132], also decreased the bind-
ing of [3H]fMLF to neutrophils [133]. Recently, propofol, a 
widely used i.v. anesthetic drug, was reported to exhibit 
FPR1 antagonist activity [134]. Propofol and its halogenated 
analogs are also high-affinity inhibitors of voltage-operated 
sodium channels [135]. Because NSAIDs, losartan, sulfasa-
lazine, and propofol exhibit various pharmacological proper-
ties, these drugs are not suitable for in vivo studies designed 
to probe the physiological role of FPR. 
Table 11. Agonist Activity of Quinazolinone Derivatives 62-
66 [74, 79, 119] 
NH
N
O
NH
O
R1
R2
A
 
62-65 
NH
N
O
NH
O
O
O
O
  
66 
 
EC50 (?M) 
# R1 R2 
FPR1 FPR2 PMN 
62 OCH3 butoxy N.A. 1.4 N.D. 
63 CH3 butoxy N.D. ?1.4 N.D. 
64 NO2 butoxy N.D. >1.4 N.D. 
65 OCH3 NO2 N.A. 0.3 1.4 
66  N.D. >1.4 N.D. 
N.D., EC50 was not reported.  N.A., no activity observed. 
Several new scaffolds for competitive FPR1 antagonists 
were discovered by Edwards et al. [120] using a flow cy-
tometry-based competition assay (Table 16). These scaffolds 
included phenyl-1,4,6,7,8,9-hexahydro-5H-pyrazolo[3,4-
b]quinolin-5-one (compound 115), 5-oxo-4-phenyl-1,4,5,6, 
7,8-hexahydroquinoline (compound 116), (Z)-5-(2-
oxoindolin-3-ylidene)-2-thioxothiazolidin-4-one (compound 
117), [(3-cyclohexylpropanoyl)amino]-4-thiophene-3-
carboxylate (compound 118), benzenesulfonamide (com-
pound 119), 4-anilino-1,2,3,4-tetrahydroquinoline (com-
pound 120), 4H-1-benzopyran-4-one (compound 121), and 
4-benzoyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one (com-
pound 122). Although seven compounds with a 2,2'-
(phenylmethanediyl)bis(3-hydroxy-5,5-dimethylcyclohex-2-
en-1-one) scaffold were reported as relatively low activity 
FPR1 antagonists with Ki values in the 1 to 32 ?M range 
[120], these compounds were also identified to be partial 
agonists, with most the potent being compound 79 (Table 
12). Thus, it appears that these partial agonists may still be 
able to desensitize cells but are probably not receptor an-
tagonists, because they can directly induce a Ca2+ flux.  
Further HTS efforts supported two of the chemotypes de-
scribed above as FPR1 antagonists, including 4H-1-
benzopyran-4-one and 4-benzoyl-3-hydroxy-5-phenyl-1H-
pyrrol-2(5H)-one [83], with compounds 123 and 124 as ex-
amples, respectively. Although nine FPR1-specific antago-
nists with the same 4H-1-benzopyran-4-one scaffold were 
reported in both publications [83, 120], SAR analysis of the 
substituents attached to the 4H-pyran-4-one and benzyl rings 
or via the carboxyl bridge is limited, and further evaluation 
will be necessary. Another FPR1 antagonist identified in the 
screening by Young et al. [83] is pyrazolo[1,5-a]pyrimidin-
7(1H)-one 125. Pyrrolidine bis-diketopiperazine 126 was 
recently described as potent and selective FPR1 antagonist 
by screening 37 different combinatorial libraries and totaling 
more than five million small molecules [123, 136]. 
Using of a flow-cytometry-based competition assay in 
“duplex” format, Edwards et al. [137] and Strouse et al. 
[138] identified three FPR2-specific antagonists with an 2-
phenylimidazo[1,2-a]pyrimidine scaffold, the most potent 
being compound 127. Other less potent FPR2 antagonists 
include anthrone derivative 128 and 2-(piperazin-1-
yl)pyrimidine 129. It should be noted, that the assay detected 
active structures, which blocked the binding of a fluorescent 
ligand to FPR on the surface of intact cells, thus detecting 
both agonists and antagonists [127, 139]. However, testing 
of possible agonist effects was not reported by Young et al. 
[83]. To evaluate if these antagonists could have agonist ef-
fects and whether receptor desensitization could explain the 
reported antagonism, we evaluated their activity in HL-60 
cells transfected with FPR1/FPR2. However, no direct ago-
nist effects were found for the most potent compounds 123 
and 127 in the Ca2+ flux assay (unpublished), indicating they 
are likely true competitive antagonists.  
Quinazolinone 130 with a hydroxyl group in the para po-
sition of benzene ring A was described as an FPR2 antago-
nist (see Tables 11 and 16). This compound did not activate 
Ca2+ flux in FPR2 transfected cells, but inhibited 
WKYMVm-stimulated Ca2+ flux, chemotaxis, and ERK1/ 
ERK2 phosphorylation in FPR2 transfected RBL cells. 
Moreover, compound 130 inhibited arachidonic acid-induced 
ear edema [119]. 
Several pyrrolidine bis-diketopiperazine-based FPR2 an-
tagonists, including compound 131, were recently identified 
by screening combinatorial libraries [123, 136]. Similar to 
quinazolinone derivatives 62/130, modification of the propyl 
functionality of FPR2 agonist 84 (see Table 12) to an isopro-
pyl yielded FPR2 antagonist 131, which is the most potent 
non-peptide FPR2 antagonist identified to date.  
Compound 132 (BVT173187; 3,5-dichloro-N-(2-chloro-
5-methyl-phenyl)-2-hydroxy-benzamide) was reported as an 
inhibitor of FPR1-dependent signals, but without effect on 
an agonist binding [85]. Although this compound did not 
inhibit FPR2-dependent responses, neutrophil responses to 
C5a and IL-8 were attenuated by this molecule, suggesting a 
broader specificity and/or interaction with various intracellu-
lar domains [85]. Indeed, the chemical scaffold of this com-
pound has similarity with other bioactive molecules, includ-
ing a potent NF-?B inhibitor IMD-0354 (N-(3,5-bis-
trifluoromethyl-phenyl)-5-chloro-2-hydroxy-benzamide) 
[140], naphtol AS-E and its derivatives, which are inhibitors 
of cyclic AMP-response element binding (CREB)-mediated 
gene transcription [141], and m-3M3FBS, which is a putative 
phospholipase C activator [142], as well as an inhibitor of 
Kv7 (KCNQ) voltage-activated potassium current [143].
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Table 12. Agonist Activity of Miscellaneous Derivatives 67-84 [45, 75, 79, 81, 116, 121, 123, 124] 
N
NH
O
NH
O
*
 
 
67 
NH
O
NH
O
N+
O-
O
Cl
 
68 
S
NH
O
O
 
 
69 
S
N
NH
NH
NH
S
O
O
 
70 
NH NH
O N
O
O
 
71 
O
NH
O
N S
 
72 
NH NH
O
O
NH
N
Cl
 
73 
NH NH
O
NH
O
 
74 
S
S
O
NH
OH
O
O
 
75 
O
S
N
N
O
OHO
 
76 
NH
O
N
NN
S
NH
O
O
 
77 
NH
N
N
NH O
 
78 
NH
O
N
O
O
O
O
 
80 
N
NH
O
N
O
Br
 
81 
NH
O
N
O
CF3
F  
82 
NH
NH
O N
NH
O
N
NH
O
 
83 
N
N
OH
O
O
N
N
NH
O
O
 
84 
O
O
O O
O
 
79 
I
HS OH
O
 
85 
NH
OH
OF
SH
 
86 
EC50 (?M) EC50 (?M)a 
# 
FPR1 FPR2 PMN 
# 
FPR1 FPR2 PMN 
67 N.A. 3.9 1.1 77 N.D. 0.045 N.D. 
68 N.A. 12.6 7.0 78 N.D. 0.2 N.D. 
69 N.A. 9.7 28.8 79 ~20.0 N.D. N.D. 
70 N.A. 10.8 8.2 80 6.6 N.A. 0.63 
71 18.6 11.1 1.9 81 N.A. 19.1 0.3 
72 19.7 15.0 23.6 82 N.A. 18.3 0.6 
73 N.D.b 0.04 N.D. 83 0.13 N.A. N.D. 
74 N.D. 0.1 N.D. 84 N.A. 0.14 N.D. 
75 N.D. 0.006 N.D. 85 N.A. ~1.0 N.D. 
76 N.D. 0.006 N.D. 86 N.A. N.D. N.D. 
aEC50 values were determined by measurement of Ca
2+ flux in FPR1- and FPR2-transfected RBL cells (compounds 67-72 and 80-82), CHO cells (compounds 73-78), FPR1-
transfected U937 cells (compound 79), or HEK-293 cells (compounds 83-84).  bN.D., no data or  EC50 was not reported.  N.A., no activity observed. 
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Table 13. FPR1 Antagonist Activity of Diamides 87-92 [84] 
NH
O
NH
R O OH
*
 
# R IC50 (?M)a 
87 
S  
0.3 
88 
 
0.08 
89 
Cl
 
0.8 
90 
 
1.3 
91 
 
0.8 
92 
N
N
 
1.6 
aInhibition of fMLF-stimulated intracellular Ca2+ flux in human neutrophils; IC50 values 
were recalculated from reported pIC50 values. 
Bile acids, such as deoxycholic acid (DCA) and che-
nodeoxycholic acid (CDCA), were reported to antagonize 
FPR1 at high concentrations (>100 ?M) [88, 89]. It should 
be noted that bile acids have multiple physiological func-
tions, including activation of the farnesoid X receptor (FXR) 
[144] and Takeda G-protein-coupled receptor (TGR5), a G 
protein-coupled bile acid receptor (GPBAR1) [145]. Both 
FXR and TGR5 demonstrate pleiotropic functions, including 
immune modulation. 
4.5. Molecular Modeling of FPR Antagonists and their 
Receptor Binding 
Docking studies of low-activity non-peptide FPR1 an-
tagonists, including sulfasalazine, losartan, phenylbutazone, 
sulpninpyrazone, several FPR1 ligands, and bile acids DCA 
and CDCA have been performed [120, 146]. These studies 
suggest that FPR1 antagonists could block the access of ago-
nists to the receptor by binding at the outer side of the trans-
membrane helices, between loops E2 and E3 [146]. The 
authors concluded that while the interaction with Tyr257 is 
crucial for anchoring the carboxylic group of the bile acids to 
the receptor, H-bonding with Thr177 and Thr265 is impor-
tant to determine the potency of bile acids.  
Both research groups that described docking studies of 
FPR1 antagonists also reported pharmacophore models for 
these antagonists. The pharmacophore model developed by 
Edwards et al. [120] was based on best docking poses of four 
FPR1 antagonists, including cyclosporin H, phenylbutazone, 
and 2 peptide FPR1 antagonists [147, 148], into a rhodopsin-
based FPR1 homology structure. This pharmacophore model 
has three points: two acceptors for H-bonding and one hy-
drophobic point. Using this model, structures of several 
FPR1 ligands were prioritized, including FPR1 agonist 79. 
Moreover, our further pharmacophore modeling also showed 
that this model is not specific for FPR1 antagonists, because 
FPR1 agonists (e.g., compound 80) also fit this model [75, 
121]. Ferrari et al. [146] described two pharmacophore mod-
els for FPR1 antagonists that contain either two hydrophobic 
centers, one H-bonding donor site, and one H-bond accep-
tor/negative site (model I) or two H-bond acceptor sites and 
three hydrophobic centers (model II).  
The present overview of FPR ligands can provide some 
general observations concerning differences between struc-
tures of agonists and antagonists. Indeed, many FPR1 an-
tagonists investigated contain OH groups, which can serve as 
H-bond donors and/or acceptors upon binding to the recep-
tor. This feature is much more characteristic for antagonists 
than of agonists. For example, FPR1 antagonists 112, 113, 
115, 116, 118, 120, 122, 128, all diamides (Table 13), and 
FPR2 antagonist 127 contain hydroxyl substituents, while 
there are no OH-containing FPR1 agonists and only a couple 
OH-containing FPR1/FPR2 agonists reported (compounds 
75, and 76). It should be noted that substitution of methoxy, 
methyl, or nitro groups with a hydroxyl group in FPR1 ago-
nists 62-64 converted them to FPR1 antagonists (e.g., com-
pound 130) [119]. The presence of OH groups in the struc-
tures of known FPR1 antagonists is in agreement with mod-
els of Ferrari et al. [146], which contain pharmacophore 
points with H-bond donor and acceptor nature. To date, there 
are no reports describing modeling of FPR2 antagonists. 
Because several potent FPR1/FPR2 antagonists were re-
cently described, further molecular modeling should be con-
ducted for determination of peculiarities of their ligand–
receptor interactions.  
5. COMPUTATIONAL MODELS FOR VIRTUAL 
SCREENING AND DESIGN OF FPR LIGANDS 
Computational drug discovery is an effective strategy for 
accelerating and economizing the drug discovery and devel-
opment process. Over the past decades, computational drug 
discovery methods, such as virtual screening, pharma-
cophore modeling, and molecular docking have been greatly 
improved [149]. Since the 3D crystal structures of FPRs 
have not yet been determined experimentally, ligand-based 
virtual screening represents an alternative approach for de-
veloping new structurally diverse FPR ligands. Among 
ligand-based virtual screening technologies, pharmacophore 
modeling and (quantitative) structure-activity relationship 
[(Q)SAR] analysis are methods for estimating properties of a 
chemical from its molecular structure. These methods have 
been used extensively in drug discovery research (reviewed 
in [150]). The pharmacophore and (Q)SAR functions can be 
useful for predicting the biological properties of virtual hits 
or untested compounds obtained from ligand-based virtual 
screening.  
5.1. (Q)SAR Models 
While a variety of molecular parameters can be used in 
the computational methods for (Q)SAR analysis [151], some 
of these parameters are complex physicochemical or 
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Table 14. FPR1 Antagonist Activity of Methionine-derived Benzimidazoles 93-104 [84] 
N
NH NH
O
O
O
S
 
93
 
N
N NH
O
S
 
99 
N
NH NH
O
O
S
 
94 
N
N NH
O
S
N  
100 
N
NH NH
O
O
S
 
95 
N
N NH
N NH
O
S
O
O
 
101 
N
NH NH
O
S
 
96 
N NH
N NH
O
S
O
O
 
102 
N
NH NH
O
S
 
97 
NH
N NH
O
O
O
S
 
103 
N
NH NH
O
S
S
Cl
 
98 
NH
N NH
O
O
O
S
 
104 
 
# IC50 (?M)a # IC50 (?M) 
93 0.5 99 2.5 
94 4.0 100 0.32 
95 4.0 101 5.0 
96 2.5 102 3.2 
97 5.0 103 0.63 
98 2.0 104 <25 
aInhibition of fMLF-stimulated intracellular Ca2+ flux in human neutrophils; IC50 values were recalculated from reported pIC50 values. 
FPR Ligand Development Current Medicinal Chemistry, 2014, Vol. 21, No. 7    19 
geometrical 3D descriptors whose calculation is associated 
with difficulties resulting from molecular flexibility. Con-
versely, topological 2D descriptors, obtainable from the 
structural formula of a compound are very attractive because 
of their simplicity. A reasonable compromise between ease 
of interpretation and ease of computation was reported by 
Carhart et al. [152], who introduced atom pair descriptors as 
features of the environments of all atoms in the 2D represen-
tation of a chemical structure. This methodology has been 
widely used in the context of fragment-based similarity 
searches, ligand-based in silico drug screening, and database 
mining [153, 154]. 
Table 15. FPR1 Antagonist Activity of Pyrazole-4-carboxa- 
mides 105-112 [86, 87] 
N
N
NH
S
O
O
NH
O
105
 
N
N
NH
S
O
O
NH
O
F
N
 
109 
N
N
NH
S
O
O
NH
O
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N
N
NH
S
O
O
NH
O
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N
N
NH
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O
O
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O
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N
N S
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O
O
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O
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N
N
NH
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O
O
NH
O
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N
N
O
NH
S
O
O
NH
O
 
112 
 
# IC50 (?M)a # IC50 (?M) 
105 2.0 109 0.025 
106 0.5 110 0.032 
107 0.08 111 0.04 
108 0.5 112 0.004 
aInhibition of fMLF-stimulated intracellular Ca2+ flux in human neutrophils or HEK 
cells expressing recombinant human FPR1; IC50 values were recalculated from re-
ported pIC50 values. 
Recently we applied atom pair descriptors to represent se-
lected set of FPR1/FPR2 agonists and obtained SAR rules, 
which were based on six atom pair descriptors [155]. Using 
binary classification tree methodology, we found that FPR1 
agonists in the series investigated could be characterized by 
simultaneously satisfying certain conditions, as described 
[155]. Good quality and high predictive ability of the SAR 
model, as well as simplicity and rapidity of calculations asso-
ciated with the binary tree algorithm, suggest promise in using 
the classification tree approach for large database mining and 
virtual screening of FPR agonists. This application of simple 
classification rules is especially attractive with the appearance 
of very large compound databases. However, virtual screening 
with highly diverse databases should be preceded by devel-
opment of more sophisticated SAR rules based on large train-
ing sets consisting of compounds with various chemical types. 
Within a series of molecules with a common scaffold, de-
riving QSAR models is useful for effective drug design. So 
far, QSAR models have not been published for FPR agonists 
or antagonists, and further efforts are necessary to develop 
such models. 
5.2. FPR Pharmacophore Models 
A pharmacophore is a model which represents the key 
physicochemical interactions that mediate biological activity 
[156]. A pharmacophore model can be used for ligand-based 
virtual screening and to characterize molecular features of 
ligands and their structural requirements for biological inter-
action [157]. Moreover, during virtual screening based on 
GPCR structure, the data set could be filtered with a simple 
pharmacophore model representative of the desired receptor 
ligands in order to exclude compounds considered to be un-
able to bind [158].  
Several pharmacophore models of FPR1/FPR2 ligands 
have been reported to date [75, 79, 120, 121, 146]. We built 
a pharmacophore model of FPR1 agonists based on field 
point methodology developed by Cheeseright et al. [113-
115]. This approach allowed us to compare diverse mole-
cules in terms of their field similarity and create an align-
ment of their bioactive conformations [159]. Although the 
results of our modeling [79] are in agreement with the three-
centered pharmacophore model obtained by Edwards et al. 
[120], our model also elucidates features not evident in the 
Edwards model. For example, the compact group of red 
spheres in the lower part of (Fig. 6) is considered a poten-
tially important characteristic of the template, likely repre-
senting interaction with electronegative features of the 
ligand-binding site. Investigation of a wider series of highly 
active FPR agonists in the future will generate more informa-
tion about the significance of these field points.  
Another useful approach to the construction of pharma-
cophore models consists of applying comparative molecular 
field analysis (CoMFA) [160], comparative molecular simi-
larity indices analysis (CoMSIA) [161], and related ligand-
based methodologies. This approach allows one to obtain a 
QSAR model along with spatial arrangement of pharmaco-
logically important areas or points. As an example, QSAR 
based on CoMFA, CoMSIA, and molecular descriptors was 
built for ligands of P2Y1, an ADP-activated GPCR [162]. 
Hence, further is needed to derive such models within series 
of structurally related FPR agonists or antagonists. 
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Table 16. Antagonist Activity of Miscellaneous Derivatives at FPR1 (Compounds 113-126, and 132) and FPR2 (Compounds 127-131) 
[83, 120, 123, 127] 
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# Ki (?M) # Ki (?M) # Ki (?M) 
113 14.0 120 12.0a 127 0.27 
114 18.0 121 2.0a 128 1.8 
115 4.0a 122 4.0 129 3.2 
116 7.0a 123 0.095 130 6.7b 
117 4.0a 124 0.55 131 0.001a 
118 11.0a 125 0.75 132 0.1 
119 3.0a 126 0.002a   
aInhibition of fluorescent ligand (WKYMVm-FITC) binding in U937 (FPR1) or RBL (FPR2) cells were used. bBinding ability (IC50) was found in competition assay [
125I]-
WKYMVm with  membranes prepared from RBL-FPR2 cells. 
 
Fig. (6). Multi-molecule template for FPR1 developed from com-
pounds 2, 79, and 81. 
5.3. Homology Models and Molecular Docking 
Molecular docking is becoming a routine technique dur-
ing the last decade because of the great success in establish-
ing 3D structures of ligand-receptor complexes and in ho-
mology modeling. Although docking is hardly applicable 
now to large database mining because of high computational 
demands, its use for small data sets of FPR agonists and 
other compounds is very helpful for understanding peculiari-
ties of interaction between ligands and receptors. Successful 
homology models of GPCRs can provide a structural basis 
for understanding ligand binding and receptor activation of 
GPCRs, and have been used for determining and comparing 
specificity profiles of related receptors, guiding drug design, 
virtual screening, and enriching the rate of ligand hits rela-
tive to a random collection of small-molecule compounds 
[163-166]. Moreover, induced fit docking (IFD) recently was 
introduced as a method that combines flexible ligand 
docking with receptor structure prediction and side chain 
refinement and could be considered as an approach for 
ligand-based protein structure optimization and homology 
modeling of GPCR [158, 167]. For drug design, it is impor-
tant to understand the extent to which crystal structures or 
homology models can be used to best predict the binding 
mode of compounds. Thus, the set of active FPR ligands 
described in this review could be useful for selection of the 
best FPR homology model and/or for ligand-based FPR 
structure optimization. 
For the identification of ligands based on novel chemo-
types, a proven technique is virtual screening through mo-
lecular docking of chemically diverse libraries that bind to 
various GPCRs [168]. Although several homology models of 
FPR1/FPR2 have been reported to date [82, 105, 116, 120, 
146, 169], most of them were used to explain the binding of 
FPR1/FPR2 agonists. One exception is the use of a combina-
tion of the FPR1 homology model and its pharmacophore 
model [120]. The combined model includes two electron 
acceptors, one hydrophobic point, and 23 sterically forbidden 
zones (i.e., exclusion spheres). This computational model 
was used for in silico screening of ~480,000 drug-like small 
molecules and improved the physical screening hit rate by 
12-fold (1.2% vs. 0.1% hit-rate in a random compound col-
lection).  
6. CONCLUSION AND PERSPECTIVES 
Although FPRs have great potential as pharmacologic 
targets for treatment of a variety of inflammatory diseases [9, 
12, 13], a key question in the field is whether FPR agonists 
or antagonists have the most therapeutic potential. An 
additional question is whether FPR agonists/antagonists 
could represent more specific and/or effective therapeutics 
than currently available treatments for these processes and 
pathologies. Indeed, studies indicate that FPRs have a num-
ber of functions outside of the immune system and are in-
volved in a variety of signaling systems. Thus, the off-target 
effects of FPR ligands in vivo may be unpredictable. Clearly, 
further studies are required to understand the complex role of 
FPRs in vivo and how they might serve as therapeutic tar-
gets. Although detailed pharmacological characterization of 
rodent FPRs is clearly interesting as a model for human 
diseases and determination of the biological roles of FPRs, 
rodent FPRs are distinct from their human counterparts and 
many agonists of human FPRs do not activate murine FPRs. 
Thus, the selection of appropriate in vivo models is also 
important to consider. 
Current small-molecule FPR ligands have been discov-
ered as result of HTS efforts and/or synthesis of new struc-
tures based on discovered hits and subsequent SAR-directed 
drug design. Because a key question in drug discovery is 
how to best prioritize and select hits for further evaluation 
from the many weakly active compounds, SAR information 
is the next step in attempts to estimate the chemical optimi-
zation potential of hits [170]. Note, however, that SAR 
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analysis of small-molecule ligands for murine counterparts 
of the human FPRs has not been performed and is clearly 
necessary if these compounds are being developed as 
therapeutics in murine models.  
Despite the increased number of FPR agonists discovered 
in recent years, pharmacokinetic analysis has only been re-
ported for one FPR2 agonist (compound 13) [98] and all 3 
known series of FPR1 antagonists [84, 86, 87]. This may 
reflect relatively weak interest from pharmaceutical compa-
nies for FPRs as perspective therapeutic targets. Indeed, only 
three companies have reported interest in development of 
FPR ligands, including Acadia Pharmaceuticals, Inc. (FPR2 
agonists) [45], Amgen, Inc. (FPR2 agonists) [76, 98], and 
AstraZeneca, R&D, Charnwood (FPR1 antagonists) [84, 86, 
87]. Furthermore, there are still no therapeutic drugs target-
ing FPRs in preclinical or clinical trials. Another possibility 
to apply such non-peptidic FPR ligands in clinical medicine 
is in the development of imaging agents. Indeed, several 
imaging conjugates based on the peptide FPR1 antagonist 
cFLFLFK have been reported, including a 64Cu conjugate for 
a positron emission tomography (PET) [171], a 99mTc conju-
gate for a single photon emission computed tomography 
(SPECT) [172], a cyanine-7 conjugate for noninvasive near 
infrared fluorescence imaging [173], and a Gd(III) contrast 
agent for magnetic resonance imaging (MRI) [174]. Thus, 
imaging agents based on small-molecule FPR agonists could 
be desirable agents imaging neutrophils at sites of inflamma-
tion. 
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ABBREVIATIONS 
Anxa12–26  = Annexin 1 fragment 2-26 
CoMFA = Comparative molecular field analysis 
CXCR = C-X-C chemokine receptor 
DCA = Deoxycholic acid 
FPR = Formyl peptide receptor 
GPCR = G protein-coupled receptor 
HIV = Human immunodeficiency virus 
HTS = High-throughput screening 
IL = Interleukin 
LPS = Lipopolysaccharide 
LTB = Leukotriene B4 
LXA4 = Lipoxin A4 
NSAID = Non-steroidal anti-inflammatory drug 
QSAR = Quantitative structure-activity relationship 
SAA = Serum amyloid A 
SAR = Structure–activity relationship 
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